CARsgen Therapeutics Holdings Ltd
HKEX:2171
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Price:
23.98
HKD
-0.17%
Market Closed
Market Cap:
HK$13.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
CARsgen Therapeutics Holdings Ltd
HKEX:2171
|
CN |
|
Wynn Resorts Ltd
NASDAQ:WYNN
|
US |
|
G
|
Gossan Resources Ltd
SWB:GSR
|
CA |
|
S
|
Synlait Milk Ltd
ASX:SM1
|
NZ |
|
Granite Real Estate Investment Trust
TSX:GRT.UN
|
CA |
|
China Bright Culture Group
HKEX:1859
|
CN |
|
B
|
Bluenord ASA
OSE:BNOR
|
NO |
|
Nippon Chemi-Con Corp
TSE:6997
|
JP |
|
Arata Corp
TSE:2733
|
JP |
|
S
|
Shanghai Universal Biotech Co Ltd
SZSE:301166
|
CN |
|
Victory Securities (Holdings) Company Ltd
HKEX:8540
|
HK |
|
NJS Co Ltd
TSE:2325
|
JP |
|
C
|
Chongqing Sulian Plastic Co Ltd
SZSE:301397
|
CN |
|
Hyakugo Bank Ltd
TSE:8368
|
JP |
|
China Feihe Ltd
HKEX:6186
|
CN |
|
Investore Property Ltd
NZX:IPL
|
NZ |
|
S
|
Solowin Holdings Ltd
NASDAQ:SWIN
|
HK |
|
Valqua Ltd
TSE:7995
|
JP |
|
C
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
US |
|
Coventry Group Ltd
ASX:CYG
|
AU |
|
Y
|
Yesil Yatirim Holding AS
IST:YESIL.E
|
TR |
Income Statement
Earnings Waterfall
CARsgen Therapeutics Holdings Ltd
CARsgen Therapeutics Holdings Ltd
Income Statement
CARsgen Therapeutics Holdings Ltd
CARsgen Therapeutics Holdings Ltd
Currency: CNY
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Interest Expense |
11
|
16
|
16
|
9
|
5
|
5
|
6
|
6
|
0
|
|
| Revenue |
26
N/A
|
26
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
6
N/A
|
39
+522%
|
84
+113%
|
126
+50%
|
|
| Gross Profit | ||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
(5)
|
(25)
|
(42)
|
(46)
|
|
| Gross Profit |
26
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
15
+812%
|
42
+188%
|
80
+88%
|
|
| Operating Income | ||||||||||
| Operating Expenses |
(613)
|
(752)
|
(806)
|
(804)
|
(785)
|
(740)
|
(577)
|
(607)
|
(184)
|
|
| Selling, General & Administrative |
(124)
|
(119)
|
(130)
|
(131)
|
(119)
|
(132)
|
(127)
|
(99)
|
(70)
|
|
| Research & Development |
(468)
|
(603)
|
(627)
|
(620)
|
(587)
|
(533)
|
(424)
|
(319)
|
(245)
|
|
| Depreciation & Amortization |
(36)
|
(45)
|
(59)
|
(71)
|
(87)
|
(76)
|
(76)
|
(46)
|
0
|
|
| Other Operating Expenses |
14
|
16
|
10
|
18
|
8
|
0
|
49
|
(143)
|
131
|
|
| Operating Income |
(587)
N/A
|
(726)
-24%
|
(806)
-11%
|
(804)
+0%
|
(785)
+2%
|
(739)
+6%
|
(563)
+24%
|
(565)
0%
|
(104)
+82%
|
|
| Pre-Tax Income | ||||||||||
| Interest Income Expense |
6
|
6
|
(85)
|
(115)
|
38
|
44
|
(46)
|
43
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(189)
|
0
|
0
|
|
| Total Other Income |
(4 156)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(4 737)
N/A
|
(719)
+85%
|
(891)
-24%
|
(919)
-3%
|
(747)
+19%
|
(694)
+7%
|
(798)
-15%
|
(522)
+35%
|
(103)
+80%
|
|
| Net Income | ||||||||||
| Tax Provision |
(8)
|
(8)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
| Income from Continuing Operations |
(4 744)
|
(727)
|
(892)
|
(920)
|
(748)
|
(695)
|
(798)
|
(522)
|
(103)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Net Income (Common) |
(4 744)
N/A
|
(727)
+85%
|
(892)
-23%
|
(920)
-3%
|
(748)
+19%
|
(695)
+7%
|
(798)
-15%
|
(522)
+35%
|
(98)
+81%
|
|
| EPS (Diluted) |
-12.26
N/A
|
-1.32
+89%
|
-1.62
-23%
|
-1.66
-2%
|
-1.34
+19%
|
-1.25
+7%
|
-1.44
-15%
|
-0.95
+34%
|
-0.18
+81%
|
|
Switch to:
Switch to:
See Also
Discover More
